Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2005

View Archived Issues

Clinical study of Sativex in patients with peripheral neuropathic pain

Tolerability and pharmacokinetics of LY-450139 assessed in healthy volunteers

Jazz Pharmaceuticals completes acquisition of Orphan Medical

Pre-NDA meeting for AzaSite

License and equity agreement for Neovacs' TNF-alpha kinoid

Emergent BioSolutions acquires Microscience

Pfizer: no evidence of increased risk of blindness among Viagra patients

ChemGenex and Stragen to accelerate development of Ceflatonin

NeuroSolutions and Sosei collaboration identifies neuropathic pain compound

Genaera reaches SPA agreement on phase III trials for Evizon

Phase III endocarditis and bacteremia trial of Cubicin meets primary endpoints

GeneMax receives primary vaccine candidate for oncology

IND submission for MS drug laquinimod

Preclinical neuroprotective effects of iptakalim suggest potential efficacy in Parkinson's disease

Preclinical and clinical data on CJC-1295 reported

SJ-8026 possesses antiangiogenic and antitumor apoptotic activities

454's ultra-deep sequencing able to detect low levels of drug-resistant HIV

Novel diagnostic agents reported in recent patent literature

New data from the IMPACT studies support the use of infliximab in psoriatic arthritis

Update on the benefits of adalimumab in arthritis

Therapeutic agents for fibrotic disorders reported by Nihon University

Telmisartan shows promise in the management of early morning blood pressure surge

Insulin glargine improves the benefits of early antiglycemic therapy in type 2 diabetes

Compounds for lipoprotein disorders, obesity, etc. in early development

Xyrem receives positive opinion for cataplexy in Europe

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...